Forum Home | Log in | Signup | My Page | Rules | FAQ | Boards | Members | Search
Replies to Msg. #1127154
.
 Msg. #  Subject Posted by    Board    Date   
59181 Re: Dow futures rally 900 points after report says Gilead drug showing effectiveness against coronavirus
   LOL And the markets still jumprd even after the truth comes out, They... 		capt_nemo   POPE 5   17 Apr 2020
 11:01 PM
59148 Re: Dow futures rally 900 points after report says Gilead drug showing effectiveness against coronavirus
   A lot of these NEW bio no name stocks sprung up Just because of the vi... 		capt_nemo   POPE 5   17 Apr 2020
 4:55 PM

The above list shows replies to the following message:

Re: Dow futures rally 900 points after report says Gilead drug showing effectiveness against coronavirus

By: Decomposed in POPE 5
Fri, 17 Apr 20 12:38 PM
Msg. 59140 of 62138
(This msg. is a reply to 59110 by capt_nemo)
Jump to msg. #  

The news about Gilead looks to be a scam designed to pump the stock and maybe the market as a whole. Friday morning may be an opportunity to buy PSTI at a VERY good price. Positive news about Remdesivir and its gigantic owner, GILD, would be a tough break for little PSTI. I wonder how many fools will be sucked in.

Over on ALEA, I see that CactusFlower has been, using the false news as a tool for criticizing "the chloroquines" and, indirectly, President Trump. CactusFlower praises Remdesivir, saying it has "better evidence than was available for the chloroquines." Note that there is no evidence! As usual, libtards manage to see what is not there and believe what is not so.
April 16, 2020

Gilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power"

by Tyler Durden
ZeroHedge.com

After a one-two punch of disappointing news for Gilead out of China, where as we reported yesterday a trial of remdesivir in Covid-19 patients with mild or moderate symptoms was suspended as no eligible patients could be recruited according to an update on ClinicalTrials.gov, which in turn followed a trial of the drug in severely ill Covid-19 patients which was also terminated for similar reasons, it felt like one or more hedge funds would seek to manipulate public sentiment - and the market - and get out of an underwater position.

They did just that at 430pm today when the low profile Statnews published a report by Adam Feuerstein, best known for doing the bidding of one or more hedge fund clients, according to which a "Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."

"Learned" from whom? A hedge fund or two who were long GILD and needed a fake news catalyst to get out? Because last time we checked, double blind, secret drug trials are, er... secret.

The report went on: "patients using Gilead's remdesivir were "seeing rapid recoveries in fever and respiratory symptoms", which is odd considering the two previous incomplete/failed trials in China. According to the report, "almost all patients were discharged in under than a week, and only two patients died."

Which actually is very bad news because as the FT reported later - this time using facts not sources - "none of the patients on the Chicago trial had been on invasive ventilation", so is it possible that the drug killed them? Maybe Feuerstein can ask his hedge fund source.

In any case, at the time the data hit Bloomberg around 4:21pm, it barely registered among the institutional audience, or even the algos, as most serious players were well aware of Feuerstein's "tactical" reputation.


It wasn't until the news was reported by CNBC about 30 minutes later - and hit the retail investing audience - that GILD stock soared 16 and the entire market took off as if someone had suddenly discovered not only a cure but also a vaccine for coronavirus.

Alas, neither happened, and as it has done on numerous occasions previously, about three hours after the news broke conveniently providing one or more hedge funds ample opportunity to offload their position in the thin after hours market, Gilead issued a statement which suggested that STAT was pumping the stock based on nothing more than "anecdotal reports" to wit:

"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."

"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19. We expect the data from our Phase 3 study in patients with severe Covid-19 infection to be available at the end of this month, and additional data from other studies to become available in May."

And so, one more attempt to ramp the market using fake news of an imminent drug has failed, with some observing that a Phase 1 drug trial is now the functional equivalent of a Phase 1 trade deal - both meaningless on their own, but with the power to send stocks surging when used tactically by unknown players.

Experts had high hopes for remdesivir because it had shown it was effective in stopping the Ebola virus replicating. Ebola shares a similar mechanism of replication with Sars-CoV-2, the virus that causes the Covid-19 disease. However, there has been no definitive statistic evidence yet that that is the case.

http://www.zerohedge.com/health/gilead-pours-cold-water-report-sent-market-soaring-anecdotal-reports-no-statistical-power


Avatar

Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months